- Poster presentation
- Open Access
The role of etanercept in juvenile dermatomyositis (JDMS) in children
Pediatric Rheumatology volume 12, Article number: P279 (2014)
Juvenile dermatomyositis is a rare autoimmune disease characterised by profound muscle weakness in addition to skin lesions, calcinosis, and underlying vasculopathy. Current treatment plans, including methotrexate and corticosteroids, are ineffective in some patients and may be associated with significant adverse events. The benefits and risks of etanercept in JDMS are not well studied.
The aim of this study is to review the benefit and safety of etanercept in JDMS patients.
We performed a single centre retrospective analysis of all consecutive JDMS patients treated with etanercept in a tertiary paediatric referral centre. Data collected included clinical and laboratory data, disease duration, the initial dose of etanercept, and other medication details. The outcome was measured by the Childhood Myositis Assessment Scale (CMAS) scored before commencing Etanercept and at 12 months follow-up.
Seven JDMS patients (5 female) were treated with etanercept. Median age at diagnosis was 64 months (36-103 months). The most frequent symptoms at diagnosis included proximal muscle weakness in all patients, constitutional features in 6, muscle pain in 5, typical skin features in 4, and arthralgia in 3 patients.
Disease duration until etanercept was 35 months (10-60 months). All children were treated with prednisolone and methotrexate prior to commencing etanercept and continued prednisolone (in reducing doses) and methotrexate concurrently.
Median duration on etanercept was 20 months (range 6-85 months). Five children ceased etanercept; three due to a flare of disease activity, one child due to transfer of care, and one child due to disease remission. Two patients still receive etanercept at time of analysis. Two children who ceased etanercept commenced monthly infliximab therapy with marked disease improvement.The median CMAS score before etanercept was 44 (range 41-47), and at 12 months after commencing etanercept the median CMAS was 46 (range 41-53).
Etanercept did not demonstrate an appreciable or reliable improvement in the disease control of JDMS. Whilst beneficial for some patients, caution should be taken when initiating etanercept for JDMS. Further multicenter studies are necessary to confirm our findings.
Disclosure of interest
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Green, K.L., Twilt, M. & Southwood, T. The role of etanercept in juvenile dermatomyositis (JDMS) in children. Pediatr Rheumatol 12 (Suppl 1), P279 (2014). https://doi.org/10.1186/1546-0096-12-S1-P279
- Infliximab Therapy